Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. The drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.

You may also be interested in...



Merck Eyes Primary Care Opportunities Despite Challenges

Two of Merck’s potential near-term launches, suvorexant for insomnia and odanacatib for osteoporosis, will enter crowded markets dominated by generics, but executives at the Citi Global Health Care conference maintain that novel mechanisms of action will address unmet market opportunities.

Merck On Track To File Novel Sleep Aid Suvorexant In 2012

Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.

Waiting For Blockbusters: Osteoporosis Market Burdened With Black Box Warnings, Reimbursement Woes, And Spare Pipelines

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel